Recent 8-K filings for ZVSA
Highest-materiality recent filing
Nasdaq to delist ZyVersa Therapeutics common stock effective ~Sep 28, 2025
- Nasdaq notified ZyVersa on Sept 14, 2025, of delisting; Form 25 to be filed on or about Sept 18, 2025.
- Stock was suspended from Nasdaq on July 17, 2025; trading on OTCQB since July 28, 2025 under symbol ZVSA.
-
ZyVersa raises $1M via convertible notes and warrants for working capital
Issued $1M aggregate principal 10% convertible promissory notes, maturing in 12 months, with a $0.02 floor price on conversion.
-
ZyVersa director Robert Finizio resigns from board effective Dec 2, 2025
Independent director Robert G. Finizio resigned as board member, Compensation Committee chair, and Audit Committee member.
-
ZyVersa reports Q3 net loss of $19.8M; cash only $0.5M, going concern risk
Cash on hand $0.5M as of Sept 30, 2025; expects month-to-month liquidity only, needs additional financing.
-
ZyVersa CMO Pablo Guzman resigns Oct 10, 2025 to focus on family
Pablo Guzman, M.D., resigned as CMO and SVP of Medical Affairs, effective October 10, 2025.
-
Nasdaq to delist ZyVersa Therapeutics common stock effective ~Sep 28, 2025
Nasdaq notified ZyVersa on Sept 14, 2025, of delisting; Form 25 to be filed on or about Sept 18, 2025.
-
ZyVersa Therapeutics common stock to trade on OTCQB from July 28
OTCQB approval received on July 25, 2025; trading commences July 28 under ticker ZVSA.
-
ZyVersa Therapeutics receives Nasdaq delisting notice; trading suspended July 17
Nasdaq Hearings Panel denied request to continue listing on the Nasdaq Capital Market.
-
ZyVersa enters warrant exercise inducement; expected gross proceeds ~$2.05M
Existing Series A-2 and A-3 warrants with $1 exercise price reduced to $0.67; holder exercises for cash.
-
Up to $10M of common stock; company controls timing and amount of sales over 24-month term.
-
ZyVersa shareholders approve up to 3.84M new shares, potentially doubling float
Shareholders approved increasing equity plan share reserve by 100,000 to 382,122 shares.
-
Zyversa receives Nasdaq delisting notice for low bid price; will appeal
Received Nasdaq letter on May 27, 2025 for non-compliance with $1.00 minimum bid price rule.
-
Marcum resigned as auditor effective April 4, 2025; CBIZ CPAs engaged April 7 after acquiring Marcum's attest practice.
-
ZyVersa raises ~$2M in private placement; special meeting adjourned without quorum
Gross proceeds of $2M from private placement of pre-funded and common warrants; pre-funded warrants priced at $0.9499.
-
ZyVersa Q3 net loss $2.4M, cash only $0.1M; Phase 2a trial expected Q1 2025
Net loss improved 17.3% to $2.4M from $2.9M YoY; R&D and G&A expenses decreased.
-
ZyVersa raises ~$1.7M via warrant exercise inducement at $2.06/share
Existing warrant holders exercise at reduced price of $2.06/share; gross proceeds ~$1.7M.
-
ZyVersa shareholders approve 150,000-share equity plan increase and up to 478,600 warrant shares
Elected Min Chul Park, Ph.D. as Class II director with 183,493 votes for, 13,425 withheld.
-
Zyversa Therapeutics enters $1.4M ATM equity offering with A.G.P.
Entered ATM Agreement with A.G.P./Alliance Global Partners to sell up to $1,397,396 of common stock.
-
ZyVersa raises ~$830k via warrant inducement at $3.46; issues 200% new warrants
Holder exercises existing Series A/B warrants at reduced price $3.46 (from $12.50), gross proceeds ~$830k.
-
ZyVersa Therapeutics executes 1-for-10 reverse stock split effective April 25, 2024
Reverse split ratio 1-for-10; approved by stockholders at special meeting on April 17, 2024.
-
ZyVersa shareholders approve reverse stock split; board sets 1-for-10 ratio
Shareholders approved reverse stock split at special meeting on April 17, 2024, with 2,058,182 votes for and 899,831 against.
Earnings & guidance
Materiality & sentiment trend
Max materiality 1.00 · Median 0.62 · Most common event other_material